Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  A M A Journal of Diseases of Children

• Publication date

  1989-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHPEDI.1989.02150230086028PMID 2816859
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis

  1987cited by this paper
• Extended High Frequency Hearing Sensitivity a Normative Threshold Study in Musicians

  1986cited by this paper
• High-frequency audiometry. Normative studies and preliminary experiences.

  1985cited by this paper
• The role of high-frequency audiometry in early detection of ototoxicity.

  1985cited by this paper
• The Quest for High-Frequency Normative Data

  1985cited by this paper
• High Frequency Audiometry

  1984cited by this paper
• Risk factors for the development of auditory toxicity in patients receiving aminoglycosides.

  1984cited by this paper
• A system for evaluating auditory function from 8000--20 000 Hz.

  1979cited by this paper
• Recommended High‐Frequency Audiometric Threshold Levels (8000–18 000 Hz)

  1972cited by this paper
• High frequency studies in school children in nine countries

  1971cited by this paper
• Preferred Method For Clinical Determination Of Pure-Tone Thresholds

  1959cited by this paper
• STREPTOMYCIN IN TREATMENT OF CLINICAL TUBERCULOSIS: A PRELIMINARY REPORT

  1945cited by this paper

• Central auditory system assessment in children and adolescents with cystic fibrosis: electrophysiology and central auditory processing

  2024cites this paper
• [Assessment of the risk of hearing loss in children with cystic fibrosis].

  2024cites this paper
• Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.

  2021cites this paper
• Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in Cystic Fibrosis

  2020cites this paper
• Prevention of aminoglycoside antibiotic-induced ototoxicity of auditory hair cells via block of mechano-electrical transducer channels or intracellular mechanisms

  2019cites this paper
• Hearing thresholds at high frequency in patients with cystic fibrosis: a systematic review

  2016cites this paper
• The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review

  2016influential citation
• Hearing loss perception in adults with cystic fibrosis

  2016cites this paper
• High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients

  2015cites this paper
• High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.

  2015cites this paper
• An analysis of ototoxicity in children: Audiological detection, clinical practice and genetic susceptibility

  2014cites this paper
• Transient evoked otoacoustic emissions and cochlear dysfunction

  2013cites this paper
• Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.

  2013cites this paper
• Chronic kidney disease: a new morbidity of cystic fibrosis or an old morbidity of diabetes mellitus?

  2011cites this paper
• Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population

  2011cites this paper
• Symptom Reporting Compared with Audiometry for the Detection of Cochleotoxicity in Patients on Long-Term Aminoglycoside Therapy

  2011cites this paper
• Egyptian Society of Ear , Nose , Throat and Allied Sciences

  2011cites this paper
• Interaction between CFTR and prestin (SLC26A5).

  2010cites this paper
• Sensorineural hearing loss in patients with cystic fibrosis

  2009cites this paper
• Efficacy, Safety, and Local Pharmacokinetics of Highly Concentrated Nebulized Tobramycin in Patients with Cystic Fibrosis Colonized with Pseudomonas aeruginosa

  2007cites this paper
• Aminoglycosides, toxicity and cystic fibrosis.

  2007cites this paper
• ENT surgery and cystic fibrosis

  2005cites this paper
• Aminoglycoside prescribing and surveillance in cystic fibrosis.

  2003cites this paper
• The prevalence of neurosensorial hearing loss among cystic fibrosis patients from Hospital de Clínicas de Porto Alegre.

  2003cites this paper
• Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis.

  2002cites this paper
• Pharmacokinetic Optimisation of Antibacterial Treatment in Patients with Cystic Fibrosis

  1998cites this paper
• Nebulised antibiotics for adults with cystic fibrosis

  1997cites this paper
• Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis.

  1997cites this paper
• Evaluation of noise-induced hearing loss by reference to the upper limit of hearing

  1995cites this paper
• [Pharmacokinetics of netilmicin in the first use in newborn infants with gestational ages greater than 34 weeks].

  1994cites this paper
• Nonselective cation and Cl channels in luminal membrane of the marginal cell.

  1993cites this paper
• Optimisation of Antibiotic Therapy in Cystic Fibrosis Patients

  1993cites this paper
• ENT surgery and cystic fibrosis.

  1992cites this paper
• Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children

  1992cites this paper
• Behavioural evidence for recovery of auditory function in guinea pigs following kanamycin administration.

  1992cites this paper
• Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.

  1991cites this paper